“Activating CB₁ cannabinoid receptor has been demonstrated to produce certain therapeutic effects in animal models of Alzheimer’s disease (AD).

In this study, we evaluated the specific contribution of CB₁ receptor to the progression of AD-like pathology in double transgenic APP/PS1 mice.

In summary, our results suggest a crucial role for CB₁ receptor in the progression of AD-related pathological events.”